Amundi Spring Works Therapeutics, Inc. Transaction History
Amundi
- $275 Billion
- Q4 2024
Shares
3 transactions
Others Institutions Holding SWTX
# of Institutions
239Shares Held
70.8MCall Options Held
151KPut Options Held
255K-
Vanguard Group Inc Valley Forge, PA7.16MShares$419 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$329 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.46MShares$203 Million5.51% of portfolio
-
Boxer Capital, LLC San Diego, CA3.42MShares$200 Million5.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.27MShares$192 Million0.01% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $3.66B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...